Back to top
more

Halozyme Therapeutics (HALO)

(Delayed Data from NSDQ)

$38.57 USD

38.57
547,082

+0.11 (0.29%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $38.55 -0.02 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for HALO

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

Halozyme Therapeutics, Inc. [HALO]

Reports for Purchase

Showing records 121 - 140 ( 181 total )

Company: Halozyme Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 121

05/16/2013

Daily Note

Pages: 8

Preliminary Roche Abstracts for GA101 Cause Concern for SC-MabThera Opportunity - Near-Term Risks in SC-HERCEPTIN Decision - Reiterate NEUTRAL

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 25.00

Research Provided by a Third Party

Company: Halozyme Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 122

05/09/2013

Company Report

Pages: 6

Q1:13 Financial Results and Update -- Awaiting CHMP sc-HERCEPTIN Decision -- Reiterate NEUTRAL

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 25.00

Research Provided by a Third Party

Company: Halozyme Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 123

05/03/2013

Industry Report

Pages: 5

LIFE SCIENCES-The Week Ahead in Life Sciences - Upcoming Events for the Week of May 6

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Halozyme Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 124

03/31/2013

Industry Report

Pages: 5

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Halozyme Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 125

03/22/2013

Daily Note

Pages: 4

Roche Partnership Risks Remain - EU HyQvia Recommendation Offers Little Upside - Reiterate NEUTRAL

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 10.00

Research Provided by a Third Party

Company: Halozyme Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 126

03/15/2013

Industry Report

Pages: 5

LIFE SCIENCES-The Week Ahead in Life Sciences - Upcoming Events for the Week of March 18

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Halozyme Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 127

02/27/2013

Company Report

Pages: 6

Q4 Results and Update - Lowering Fair Value to $6 from $13

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 25.00

Research Provided by a Third Party

Company: Halozyme Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 128

02/01/2013

Daily Note

Pages: 7

No Backpedaling from ROCHE on sub cu HERCEPTIN during the US Analyst Presentation -- REITERATE NEUTRAL

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 25.00

Research Provided by a Third Party

Company: Halozyme Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 129

01/30/2013

Company Report

Pages: 7

Downgrading to NEUTRAL and Removing from Best Ideas List -- ROCHE Downplays subcutaneous HERCEPTIN

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 25.00

Research Provided by a Third Party

Company: Halozyme Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 130

12/21/2012

Company Report

Pages: 6

Partnering Progress Validates Technology; Additional Deals Likely in Near-term, Potentially by Year-End 2012 - Reiterate OUTPERFORM and Best Idea

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 25.00

Research Provided by a Third Party

Company: Halozyme Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 131

12/07/2012

Industry Report

Pages: 5

LIFE SCIENCES

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Halozyme Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 132

12/03/2012

Industry Report

Pages: 5

BEST IDEAS LIST-Best Ideas List -- November 2012 Performance

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Research Provided by a Third Party

Company: Halozyme Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 133

11/16/2012

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of November 18

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Halozyme Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 134

11/09/2012

Company Report

Pages: 7

Q3:12 Update - Insulin Pump Opportunity Remains

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 25.00

Research Provided by a Third Party

Company: Halozyme Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 135

10/08/2012

Company Report

Pages: 8

Raising FV to $17 - Analyst Day Takeaways: 2013 Hylenex Insulin Pump Upside and HTI-501 in Cellulite Partnering Opportunities

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 25.00

Research Provided by a Third Party

Company: Halozyme Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 136

10/01/2012

Daily Note

Pages: 5

ESMO Herceptin Data Supports Current Length of Treatment - Preserves Herceptin SC Opportunity - Reiterate OUTPERFORM and BEST IDEA

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 10.00

Research Provided by a Third Party

Company: Halozyme Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 137

09/28/2012

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of September 30.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Halozyme Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 138

09/28/2012

Daily Note

Pages: 4

Analyst Day Preview: UpsideOpportunities in Insulin Delivery

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 10.00

Research Provided by a Third Party

Company: Halozyme Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 139

09/10/2012

Industry Report

Pages: 44

September 2012 Potential Catalysts & Milestones - Monthly Update

Provider: WEDBUSH SECURITIES INC.

Price: 100.00

Research Provided by a Third Party

Company: Halozyme Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 140

09/07/2012

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of September 9, 2012

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party